PAS
CSTL icon

Park Avenue Securities’s Castle Biosciences CSTL Stock Holding History

Park Avenue Securities’s Portfolio CSTL Stock Details CSTL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-6,478
Closed -$291K – 1128
2022
Q1 		$291K Buy
+6,478
New +$268K 0.01% 964
2021
Q4 		– Sell
-3,670
Closed -$244K – 1107
2021
Q3 		$244K Buy
3,670
+632
+21% +$44.5K ﹤0.01% 931
2021
Q2 		$223K Buy
+3,038
New +$201K ﹤0.01% 952

Other funds holding CSTL

WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
GIM
Granahan Investment Management Waltham, Massachusetts $2.07B AUM 56.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
KCM
Kornitzer Capital Management Shawnee Mission, Kansas $4.65B AUM 23.83% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
PCM
Palisade Capital Management Fort Lee, New Jersey $3B AUM 14% 1-Year Est. Return

Park Avenue Securities's CSTL Position: Q2 2022 in Review

Park Avenue Securities sold out of Castle Biosciences (CSTL) in Q2 2022, closing a stake of 6,478 shares — an estimated $291K sold.

Park Avenue Securities first reported a position in CSTL in Q2 2021 and held it in 3 quarters. The position peaked at $291K in Q1 2022. 146 funds tracked by Wall St. Rank hold CSTL as of Q2 2022.

  • Park Avenue Securities reported no remaining Castle Biosciences position as of Q2 2022 after selling out during the quarter.
  • Park Avenue Securities sold 6,478 Castle Biosciences shares in Q2 2022, an estimated $291K.
  • Park Avenue Securities first reported a position in Castle Biosciences in Q2 2021 and held it in 3 quarters.
  • Park Avenue Securities's Castle Biosciences position peaked at $291K in Q1 2022.
  • 146 funds tracked by Wall St. Rank held Castle Biosciences as of Q2 2022.

Based on Park Avenue Securities's 13F filing for Q2 2022, filed 27 Jul 2022.